Peptide Protocol
Peptide Protocol
 App Store

MOD-GRF (1-29): the complete guide

MOD-GRF (1-29), also sold as CJC-1295 without DAC, is a stabilized analog of the first 29 amino acids of human GHRH. Commonly supplied as 2 mg lyophilized vials, it produces a short, pulsatile GH release (half-life ~30 minutes) and is typically paired with a GHRP like Ipamorelin. Unlike CJC-1295 with DAC, it preserves natural GH pulsatility rather than elevating baseline GHRH tone.

Written by Peptide Protocol Editorial Medically reviewed per our review process Last reviewed
ClassGHRH analog (short-acting)
Half-lifeApproximately 30 minutes
Typical dose100 mcg per injection, 1–3x daily (often pre-bed and/or post-workout)
CategoryGrowth hormone axis
Research usePulsatile GH release research, short-cycle GH-axis protocols, training-timed GH pulses
FDA statusNot FDA approved. Research use only in the US.

How MOD-GRF (1-29) works

MOD-GRF binds pituitary GHRH receptors, triggering a brief GH-releasing signal. Structural modifications protect it from rapid enzymatic degradation compared to native GHRH, but it lacks the DAC albumin-binding arm that extends CJC-1295 with DAC to a days-long half-life.

Typical MOD-GRF (1-29) dosage

Commonly reported research ranges: 100 mcg per injection, 1–3x daily (often pre-bed and/or post-workout).

Dose should always be individualized. Factors that influence it include bodyweight, research goal, tolerance, and specific compound batch. The information below is educational, not a prescription.

How to reconstitute MOD-GRF (1-29)

A widely used reconstitution for a 2 mg vial is 2 ml of bacteriostatic water. With a typical 100 mcg dose this works out to the unit count shown in the calculator below.

Open the MOD-GRF (1-29) reconstitution calculator →

Pre-filled with the common 2 mg + 2 ml ratio. Adjust for your own vial.

Half-life and administration frequency

Approximately 30 minutes.

This half-life informs how often MOD-GRF (1-29) is typically dosed. Shorter half-lives usually mean more frequent dosing to maintain plasma levels; longer half-lives allow daily, weekly, or less-frequent administration depending on the compound.

Reported side effects

This list reflects effects reported in available literature or user logs. It is not exhaustive. Adverse reactions should be discussed with a qualified clinician.

Common MOD-GRF (1-29) stacks

Storage and handling

Lyophilized: refrigerated. Reconstituted: refrigerated, use within 14–28 days.

FDA and regulatory status

Not FDA approved. Research use only in the US.

MOD-GRF (1-29) clinical trials and evidence

For clinical-trial and primary-literature context, start with the sources below. We prioritize official drug labels, ClinicalTrials.gov records, and PubMed-indexed literature when available.

Track your MOD-GRF (1-29) protocol on iPhone

Peptide Protocol logs every dose, calculates reconstitution for you, and keeps your full protocol on one calm screen.

See the app →

Frequently asked questions

What is MOD-GRF (1-29)?

MOD-GRF (1-29), also sold as CJC-1295 without DAC, is a stabilized analog of the first 29 amino acids of human GHRH. Commonly supplied as 2 mg lyophilized vials, it produces a short, pulsatile GH release (half-life ~30 minutes) and is typically paired with a GHRP like Ipamorelin. Unlike CJC-1295 with DAC, it preserves natural GH pulsatility rather than elevating baseline GHRH tone.

How does MOD-GRF (1-29) work?

MOD-GRF binds pituitary GHRH receptors, triggering a brief GH-releasing signal. Structural modifications protect it from rapid enzymatic degradation compared to native GHRH, but it lacks the DAC albumin-binding arm that extends CJC-1295 with DAC to a days-long half-life.

What is a typical MOD-GRF (1-29) dose?

Commonly reported ranges are 100 mcg per injection, 1–3x daily (often pre-bed and/or post-workout). This is research information, not a recommendation — dosing should be individualized under clinical guidance.

What is the half-life of MOD-GRF (1-29)?

Approximately 30 minutes. This influences how often it is administered.

How do you reconstitute MOD-GRF (1-29)?

A common approach is to add 2 ml of bacteriostatic water to a 2 mg vial. Use the reconstitution calculator for exact unit counts.

What are the side effects of MOD-GRF (1-29)?

Injection-site reactions; Transient flushing or head pressure; Numbness or tingling (infrequent); Water retention.

Is MOD-GRF (1-29) FDA approved?

Not FDA approved. Research use only in the US.

Are there clinical trials for MOD-GRF (1-29)?

Registered or published clinical-trial sources for MOD-GRF (1-29) are listed in the references section below. Evidence depth varies widely by compound, so check the cited trial registries and primary literature before relying on any claim.

References

  1. MOD-GRF / CJC-1295 without DAC literature — National Library of Medicine. Research on GHRH(1-29) analogs with tetrasubstituted stabilization
  2. Teichman et al. — GHRH analog prolonged stimulation — PubMed. Comparator studies between with-DAC and without-DAC GHRH analogs
  3. GHRH analog clinical trial records — ClinicalTrials.gov. Registered studies

Sources listed above were used to verify the claims on this page. See our editorial policy for how we source information.

Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.